Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
Cyclacel Pharmaceuticals announced its participation in the 2022 BIO CEO & Investor Conference from February 14-17, 2022. The event will include 1-on-1 virtual meetings with senior management and an on-demand presentation available from February 11, 2022. Cyclacel focuses on developing innovative cancer medicines, including fadraciclib, a CDK2/9 inhibitor, and CYC140, a PLK1 inhibitor. Interested parties can access the presentation on Cyclacel's website for 90 days post-conference.
- None.
- None.
BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in the 2022 BIO CEO & Investor Conference on February 14-17, 2022.
Conference details can be found below:
- BIO CEO & Investor Conference: virtual meetings and on-demand presentation (available on conference site February 11, 2022)
Date: 1-on-1 virtual meetings with senior management February 14-17, 2022
Registration Link
The presentation can be accessed for 90 days and can be found on the Cyclacel website at www.cyclacel.com.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the potential effects of the COVID-19 pandemic, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
| Company: | Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
| Investor Relations: | Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, ikoffler@lifesciadvisors.com |
© Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
FAQ
What is the date of the 2022 BIO CEO & Investor Conference for Cyclacel (CYCC, CYCCP)?
How can I register for the 2022 BIO CEO & Investor Conference for Cyclacel Pharmaceuticals?
Where can I access Cyclacel's presentation from the 2022 BIO CEO & Investor Conference?
What innovative medicines is Cyclacel Pharmaceuticals developing?
What is the focus of Cyclacel Pharmaceuticals' pipeline?
